Accelerating CHO Media Development: From Screening To AI Design

Evaluating Modular CAR T Manufacturing Workflows

Speed Meets Precision: Accelerating Oncology With Smarter Data

Scaling Cell And Gene Therapy Manufacturing

Annex 1 In Practice: Turning CCS Into Cleanroom Design

De-Risking The Path To GMP Manufacturing At Another Organization

Challenges And Opportunities For MSC Expansion Workflows

Beyond The Starting Material: A Path To GMP Manufacturing Success

Scaling AAV Manufacturing To 1000 L: Strategies For Robust Production

Driving Productivity Across The Antibody Manufacturing Workflow

De-Risking Cell Culture Media Scale-Up For Late-Stage Manufacturing

Beyond Breakdowns: Building A Culture Of Proactive Maintenance

Accelerating CHO Media Development: From Screening To AI Design

Evaluating Modular CAR T Manufacturing Workflows

Driving Productivity Across The Antibody Manufacturing Workflow

De-Risking Cell Culture Media Scale-Up For Late-Stage Manufacturing

Driving Measurable Productivity Gains In CHO Cell Culture

The Future Of Cell Culture Media Development

From Data To Decisions: AI And Multi-Omics For Cell Culture Development

How Modular Workflows Are Redefining CAR T Manufacturing

Reducing Particulate-Related Batch Risk In Bioprocessing

How Intensified Upstream Processing Improves Scale-Up And Tech Transfer

Generate Stable High-Producing Clones In 14 Weeks

Using Residual DNA Quantification Data To De-Risk mAb Development

Efficient mAb Development With A Flexible Purification Toolkit

CAR-T Strategy In 2026: Scaling Autologous, Advancing Allogeneic

Maximizing Performance And Quality In Fed-Batch And Perfusion-Based IgG Productions Customer Interview

How MacroGenics Increased mAb Titers By Up To 80% In Scale-Up

Boost CHO Cell Protein Production By Up To 146% With Efficient-Pro™ Feed Solutions

Driven By Performance: Empowering Biotech Innovation From Lab To Life

Defined Media, Defined Results: Scaling E. coli From Bench To Fermenter

A Derivatization-Free LCMS Assay For 4β-hydroxycholesterol

Streamline Your mRNA Purification Steps

Is The Sensitivity Of Optical Biosensors Important?

Elucidating The Role Of IL-18 In NSCLC Integrated Analysis

Validation Of An LCMS Hybrid Assay With EVOSEP Cleanup

Plasmid Complexity And The Push For Stronger CGT Material Control

High Efficiency Cell Engineering From Concept To Clinic

Why Material Definitions Matter In Cell And Gene Therapy

Can You Run Crude Samples Using An SPR Instrument?

How To Best Optimize mRNA Production Workflows

Major Advancements In mRNA

LC/MS Method For Measurement In Human Plasma

Structuring CGT Deals for the Long Term with Troutman Pepper Locke's EA Weeks, J.D., Ph.D.

Shaping Drug Development by Starting with the Disease with Roche's Sylke Poehling, Ph.D.

Why Autoimmune CAR T Needs a New Patient-Centered Playbook with Dr. Panteli Theocharous

Reimagining Solid Tumor Immunotherapy Through Engineered Tregs with CoRegen's Dr. Sonal Gupta

Rewriting the Playbook for Stargardt Disease with Atsena Therapeutics' Shannon Boye, Ph.D.

How Precision Oncology Is Redefining Cancer Drug Development with Aprea Therapeutics' Dr. Oren Gilad

Exploring Dendritic Cell Therapy for Solid Tumors with Diakonos Oncology's Jay Hartenbach

Cell & Gene: The Podcast Presents: Better Biopharma's Editors' Roundtable — A Midyear Look at the 2026 Life Sciences Industry

Why In Vivo Therapies Are Moving Toward the Clinic with Ascidian Therapeutics' Dr. Mike Ehlers

Reimagining In Vivo Gene Editing Through Base Editing and Targeted Delivery with Beam Therapeutics' Gopi Shanker, Ph.D.

Advancing CAR T for Drug-Free Remission in Autoimmune Disease with Kyverna Therapeutics' Dr. Naji Gehchan

The Future of In Vivo Gene Editing and Clinical Translation with Precision Biosciences' Cassie Gorsuch, Ph.D.

Discover The Benchtop DynaDrive Single-Use Bioreactor

How To Maintain A Nuclease Free Environment During mRNA Production

A Next-Generation CHO Host For High Producing Clones

Streamline Your mRNA Purification Steps

Risk Mitigation Strategies

Simplify Your Process Of Choosing An Optimal Resin

Cytovance Customer Testimonial: Thermo Scientific Single-Use Technologies

Scaling Viral Vectors

Efficient-Pro Medium And Feed (Why Choose Pro)

DNA Sizing Data & Quantifying Residual HEK293 Host Cell DNA

Nunc Standard Closed Cell Factory System

NovaSeptum® GO Sterile Sampling: Benefits Of A Fully Harmonized Solution

Regulatory And Biosafety Testing Expertise

The Power Of Partnerships And The Rise Of iPSC

Early-Phase Whole-Body PK

What Is Causing Limited Bioavailability

Biopharma Resilience: Bionova Scientific Talks Capacity, Speed, And Agility

Closing Ancillary Processes: The New Bottleneck In Cell and Gene Therapy

Selecting The Right CMO For Your Gene Therapy

Risk Mitigation Strategies

Breaking Down Shipping

Regulatory Considerations For An Optimized Cold Chain

Thermo Fisher Scientific Single-Use Global Manufacturing Network

Biopharma Supply, Reimagined: Blarney, A Climate-Neutral Facility For Best-In-Class Filters

mRNA For Cancer Immunotherapy 2024 Outlook | Audience Q&A

Comparing Manual Vs. Automated Processing And Thawing Systems

Supply Chain And Operational Challenges Facing mRNA

A Dedicated Team To Safely Store Your Cell And Virus Banks

Balancing Innovation With Manufacturability When GMP-Grade Is Unavailable

Inventory Management, Staff Training, And Timeline Optimization

Supporting The Global Biopharma Industry With Single-Use Capacity Expansion

Enabling Large-Scale Lentivirus Manufacturing With A Reliable Stabilizer

Manufacturing Re-Engineered: Unlocking Global Access & Scale Out Economics

Enhancing Particle Recovery And Infectivity In Viral Vector Purification

Smart Manufacturing Decisions For Scalable Gene Therapy Success

From Bench To Bioproduction: Scalable MSC Expansion

Cell Handling Across Cell Types

High-Precision Fluid Management For Cell-Based Applications

Enhancing CGT Analytics And Quality Control With Digital PCR

Non-Viral Delivery Of Complex Cargos For Large-Scale CAR-T Manufacturing

Quantifying Potency In Cell & Gene Therapy

Integrated Reagent Solutions For CAR-T/NK Development And Manufacturing

How Raw Materials, Media Composition, and Process Decisions Shape Therapy Development

Scaling Next-Gen MSC Therapies Without Scaling Risk

Solving Vector Yield Challenges in In Vivo CGT

How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline

Distributed Manufacturing for CGT: Rent, Lease, or Buy in an Era of Overcapacity?

Materials Matter: Ensuring Quality Of CGT Materials

Building Smarter Cell Therapies With AI And Synthetic Biology

2026 Regulatory Roadmap

Driving Efficiency, Reducing Costs In Multi-Modal CGT Manufacturing

Viability On The Line: Defining Minimum Quality For CGT Raw Materials

Designing Early Manufacturing For Long-Term Success In CGT

Building The Future Of Cancer Immunotherapy Through Allogeneic NK Cell Innovation

Redefining CGT With Exosomes And EVs

Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More

Unlocking The Potential Of iPSC Therapies In Regenerative Medicine

Emerging Manufacturing Technologies For Cell Therapies

Optimizing Storage Solutions For Allogeneic iPSCs

2025 CGT Regulatory Outlook

Unlocking The Full Potential Of AAV-Mediated Gene Delivery

Inside The Most Promising Non-Viral Approaches For Genetic Engineering

From Bottleneck To Breakthrough: Reimagining The mRNA Therapeutics Supply Chain

Modernizing CAR-T Manufacturing: Is Point Of Care The Future?

Top Strategies To Reduce Off-Target Effects For Safer Genome Editing

Inside Next-Gen Platforms For Cell Therapy Manufacturing

Unlocking The Future Of Allogeneic Cell Therapy For Oncology

Stem-Cell Derived Therapies: From Source To Site

How To Reduce Batch-to-Batch Variation In Cell Therapy Manufacturing

2024 Regulatory Outlook With FDA's Drs. Peter Marks And Nicole Verdun

Considerations For Investing In Your Gene Therapy's Automation Framework

mRNA For Cancer Immunotherapy: 2024 Outlook

Are We There Yet? Roadmap(s) To Higher Quality AAV

Optimizing Your Cold Chain For Cell Therapies

Stability To Scalability: The Future Of Viral Vector Therapies

Regulating The CGT Workflow To Improve Patient Safety

Driving Down COGS: Automation's Role In Cell Therapy Manufacturing

Major Trends In Next-Gen RNA Engineering

Building An In-House Cell & Gene Manufacturing Facility: Best Practices & Lessons Learned

Scaling Cell Therapies Part 2: Establishing Comparability In Manufacturing

Tackling Cell And Gene Therapies' Top 3 Regulatory Impediments

Evaluating Translational Research Tools For CGTs

Scaling Cell Therapies: Auto vs. Allo

Advancements In Targeted mRNA Delivery

Win The CGT Talent Fight: How To Find And Retain Experts

Kite Pharma's Ultimate Supply Chain Test - A Q&A With Their 4-Exec Panel On Overcoming The Pandemic's Disruption

The Therapeutic Potential Of Exosomes

The Future of CRISPR-Engineered Stem Cell Therapies

Regulatory And Biosafety Testing Expertise

Strategies To Reduce Regulatory Risks In Gene Therapy

Key Regulatory Challenges, Innovations, And Opportunities For CGT In 2025

How The FDA's 2024 Draft Guidances Will Influence CGT Regulation In 2025

Why Clinical Requirements Change: Dr. Peter Marks on Pre-IND Meeting Pathways

Congruence And Divergence In Global Regulatory Approvals

Navigating Global Regulations, Equity Challenges, And The Future Of Patient Access

Making USP Guidance Actionable For CGT Materials

Ensuring Consistent Removal Of Residual Impurities

How The FDA Strengthens Industry Collaboration

mRNA For Cancer Immunotherapy 2024 Outlook | Audience Q&A

Other CGT Regulatory Challenges

Simplifying Bioprocess Data Collection

CGT's Main Opportunities To Meet Regulatory Requirements

CMC Comparability: Transitioning to Commercial Manufacturing with Dr. Nicole Verdun

Assessing Residuals In Processing And Fill/Finish For iPSCs

How The New Administration Could Shape FDA Oversight, Compliance, And Guidance In 2025

Lower Variability For Viral Titer Determination

Focal Points for 2024: Dr. Verdun and Dr. Marks Talk Regulatory Challenges for Cell-Based Therapies

How Past Gene Therapy Approvals Are Shaping the Future with Dr. Peter Marks

2025 CGT Regulatory Outlook | Audience Q&A

Race To The Regulatory Finish Line: Dr. Nicole Verdun Talks Efficiencies In Platform Technologies

Regulatory Challenges And Future Outlook For iPSC Therapies

A Straightforward Path Toward Regulatory Compliance & Data Integrity With Your Microbial Testing Systems

Dr. Peter Marks Talks a Standardized Playbook for Gene Therapy Manufacturing

Inside The Phased, Risk-Based Approach For CGT Materials

A CDMO Perspective: Bioprocess Automation And Data Management

What's New for 2024: Dr. Nicole Verdun Offers a Look Inside The Office Of Therapeutic Products

Mitigate Clinical Risk In Cell Therapy Development With A GMP Compliant Process

MilliporeSigma Bio-Expo Live February 2025: Upstream Bioprocessing

Executive Roundtable: Cell Therapy Predictions For 2025 And Beyond

Prioritizing Quality, Fit, And Supplier Reliability In CGT Materials

Challenge #3: Lack Of Animal Models

Bridging Analytical Gaps To Ensure CGT Material Quality

Patient Data's Impact On CMC Robustness

Tackling Cell And Gene Therapies' Top 3 Regulatory Impediments: Audience Q&A

Cell And Gene Therapy Innovations

Master The 2-Point Calibration Process To Maintain Data Integrity

Challenge #1: The Changing Regulatory Landscape

Challenge #2: Rare Or Ultra-Rare Study Design Considerations And Use Of Existing Data

Future Proof Process Design Through Risk-Focused Decisions, Automation Readiness, And Regulatory Pragmatism

Growing And Scaling A Radiopharmaceuticals Company With AdvanCell's Philina Lee, Ph.D.

Finding New Opportunities In Obesity With Moonwalk Bioscience's Alex Aravanis, M.D., Ph.D.

Biotech Finance And Investor Update With Independent Board Director Allan Shaw

Funding A Virtual Biotech Without Institutional Capital With Sarcomatrix's David Craig

Picking Biotech Winners Beyond The Hype Cycle With Andera Partners' Olivier Litzka

Biotech Investing At The Earliest Stages With Santé Ventures' Omar Khalil

Getting To A First Product Approval With Celcuity's Brian Sullivan

Cell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings

A Rescue Model For Shelved Drug Candidates With Annette Bakker, Ph.D. And Andrew Lo, Ph.D.

Using Genetics To Discover New Treatments With Regeneron Genetics Center's Aris Baras, M.D.

Late-Stage Development And Commercial Planning With CervoMed's Matt Winton, Ph.D.

BoB@BIO: Biotech In The Balance With Ovid Therapeutics' Dr. Jeremy Levin

2026 Regulatory Updates And Operation TrialBlazer

Focusing On Quality Unit Independence With Tatyana Matveeva, Ph.D.

Developing Multi-Targeted T-Cell Engagers With Deck Bio's Johanna Kaufmann

Fixing AAV Recovery With Siren Biotechnology's Nathalie Clément, Ph.D.

Digitalizing The Biopharma Ecosystem With Kat Kozyrytska

Modulating Multispecific Manufacturability With AP Biosciences' JJ You, Ph.D.

The Facility Master Planning Playbook With Herman Bozenhardt

Cell Therapy Without The Cells: Building A Therapeutic Secretome With Noveome Biotherapeutics' Larry Brown, Sc.D.

The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry

Validation Challenges Facing Advanced Single-Use Technologies

Aligning Upstream And Downstream Development (Part 2)

Aligning Upstream And Downstream Development (Part 1)